GHK-Cu Research Review | Published Studies

Written by: Stuart Ratcliff and Kai Reviewed by: Chameleon Peptides Research Team Last reviewed: July 11, 2026

← Back to GHK-Cu product page

Compound Overview: GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide first identified in human plasma by Loren Pickart in 1973. Its molecular formula is C₁₄H₂₄CuN₆O₄ (molecular weight: 403.93 g/mol, CAS: 49557-75-7). The peptide forms a high-affinity complex with copper(II) ions and is found endogenously in plasma, saliva, and urine, with plasma concentrations declining with age. GHK-Cu appears in preclinical literature as a model compound for extracellular-matrix signaling, gene-expression modulation, and copper-complex chemistry.

GHK-Cu Gene-Expression Literature

A review in the International Journal of Molecular Sciences examined GHK-Cu in the context of gene-expression datasets, including Broad Institute Connectivity Map observations. The article discusses transcriptional signatures associated with GHK exposure across extracellular-matrix, inflammatory-pathway, and cellular-stress marker categories.

The review reports broad gene-expression changes across thousands of measured transcripts. This page presents those findings as pathway-literature context for laboratory research, without framing the compound as producing a customer-facing physiological outcome.

Citation: Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu peptide review in gene-expression datasets. International Journal of Molecular Sciences. 2015;16(12):20518-20538. doi:10.3390/ijms160920518. PubMed PMID: 26350518

Skin Cell-Culture and Matrix Pathway Literature

A BioMed Research International review surveyed GHK-focused literature in skin cell-culture systems and animal-model contexts. The summarized mechanisms include fibroblast markers, collagen-associated signaling, angiogenesis markers, and extracellular-matrix pathway observations.

Citation: Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide review of skin-model cellular pathways. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PubMed PMID: 26236730

Oxidative-Stress Pathway Literature in Cell and Neural-Tissue Models

A peer-reviewed pathway article reviewed GHK-Cu as a copper-binding tripeptide model in oxidative-stress, copper-homeostasis, and gene-expression research. The discussion centers on in vitro assays and pathway-level observations relevant to neural-tissue model systems.

Citation: Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu oxidative-stress and gene-expression pathway review. oxidative-stress pathway journal. 2012;2012:324832. doi:10.1155/2012/324832. PubMed PMID: 22666519

Aged Mouse Model and Gene-Expression Literature

A 2020 review in the International Journal of Molecular Sciences surveyed GHK datasets across aged mouse models and cell-system gene-expression experiments. In the behavioral dataset, 28-month-old C57BL/6 male mice were assigned to a defined GHK exposure protocol and evaluated with learning-paradigm endpoints.

The review discusses reported differences in learning-paradigm measures alongside transcriptomic observations in aged-cell systems. The authors frame GHK as a tripeptide model for studying extracellular-matrix signaling, oxidative-stress response genes, inflammatory-pathway markers, and age-associated transcriptional patterns.

Citation: Pickart L, Vasquez-Soltero JM, Margolina A. GHK tripeptide review covering aged-model and gene-expression datasets. International Journal of Molecular Sciences. 2020;21(19):7261. doi:10.3390/ijms21197261. PubMed PMID: 35083444

Neural Gene-Expression Literature

A Brain Sciences article examined GHK-associated gene-expression patterns relevant to nervous-system model literature. Using Connectivity Map data, the authors discussed genes associated with neural development markers, synaptic signaling categories, neurotransmitter pathway markers, and cellular-stress response pathways.

The analysis identified GHK-associated transcript changes across nervous-system pathway categories, including nerve-growth-factor signaling, synaptic-plasticity markers, antioxidant-defense genes, inflammatory-pathway markers, and apoptosis-related markers. This page summarizes those observations as laboratory literature context only.

Citation: Pickart L, Vasquez-Soltero JM, Margolina A. GHK gene-expression review in nervous-system pathway datasets. Brain Sciences. 2017;7(2):20. doi:10.3390/brainsci7020020. PubMed PMID: 28208807

Limitations and Current Knowledge Gaps

The research summarized on this page reflects findings from preclinical models (primarily rodent and in vitro studies). Several important limitations should be acknowledged when evaluating this evidence:

Lack of human clinical trials: No large-scale, randomized controlled trials in humans have been completed for most research peptides, including GHK-Cu — Published Research. Animal data does not directly translate to human outcomes.
Dosing uncertainty: There are no standardized, clinically validated dosing protocols. Doses used in animal studies may not be relevant to human applications.
Unknown long-term safety profile: Long-term toxicity, chronic administration effects, and potential off-target biological interactions remain unstudied.
Regulatory status: GHK-Cu — Published Research is not approved by the FDA or other major regulatory agencies for human therapeutic use. Regulatory classification varies by jurisdiction.
Publication bias: Positive results are more likely to be published than negative findings, which may inflate the apparent strength of evidence.

Researchers should evaluate these findings in context and avoid extrapolating preclinical results to clinical recommendations.

Disclaimer: This page is provided for educational and informational purposes only. GHK-Cu is a research compound intended for laboratory use only. The studies summarized above were conducted in animal models, in vitro systems, and gene expression databases. This information does not constitute medical advice and should not be interpreted as a recommendation for human use. GHK-Cu is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Chameleon Peptides sells research compounds strictly for scientific investigation purposes.

Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.